Loading...
  • mice
  • To specifically investigate microglia-mediated effects in a model of neuropathic pain and overcome the methodological limitations of previous approaches exploring microglia function upon nerve injury, we selectively ablated resident microglia by intracerebroventricular ganciclovir infusion into maleCD11b-HSVTK-transgenic mice, which was followed by a rapid, complete, and persistent (23 weeks) repopulation of the CNS by peripheral myeloid cells. (ovid.com)
  • D-F) Tumor burden (D), microvessel density (E), and myeloid cell composition (F) in mice treated with sorafenib plus anti-Gr1. (nih.gov)
  • G-I) Tumor burden (G), microvessel density (H) and myeloid cell composition (I) in mice treated with sorafenib plus anti-CSF1. (nih.gov)
  • CD11b(+) myeloid cells isolated from tumors of treated mice expressed lower levels of arginase-1 and higher levels of inducible nitric oxide synthase (iNOS), and were less immunosuppressive ex vivo, which translated into a significantly reduced tumor-promoting capacity in vivo when these cells were coinjected with tumor cells. (nih.gov)
  • A . Mice were inoculated s.c. with CR Myc-CaP cells. (nih.gov)
  • B . Mice were inoculated s.c. with B16-h5T4 cells and treatment with tasquinimod was initiated the day after inoculation and continued throughout the experiment. (nih.gov)
  • D. Lungs of WT and Tnfα −/− mice 47 days after LLC inoculation (2×10 5 cells). (nih.gov)
  • D. RNA was extracted from lungs of WT or Tlr2 −/− mice at indicated times after LLC inoculation (2×10 5 cells). (nih.gov)
  • Smooth muscle protein 22 alpha-Cre is expressed in myeloid cells in mice. (nih.gov)
  • Given the known contributions of myeloid cells to cardiovascular phenotypes, caution should be taken when interpreting data using SM22α-Cre mice to investigate smooth muscle specific functions. (nih.gov)
  • B. GFP expression in Gr-1 + cells in neutrophils (R1) or monocytes/lymphocytes (R2) gates from blood of LFC and DNMAML2 mice produced by crossing SM22 -Cre(4746) mice with floxed DNMAML-GFP mice. (nih.gov)
  • Here, we demonstrated that the in vivo injection of recombinant human IL-15 (200 µg/kg) or murine IL-15 (3 µg/kg) to tumor-bearing NOD- SCID-IL2Rg−/− (NSI) mice resulted in increased tumor progression and CD45+ CD11b+ Gr-1+ CD215+ cell expansion in the tumors and spleen. (frontiersin.org)
  • In B16F10-bearing C57BL/6 mice model, we found that murine IL-15 has antitumoral effect since the activation and expansion of CD8+ T cells with murine IL-15 treatment. (frontiersin.org)
  • These ImC accumulate in large numbers in spleens, lymph nodes, and tumor tissues of tumor-bearing mice and are comprised of precursors of myeloid cells. (nih.gov)
  • Neither ImC from control mice nor progeny of tumor-derived ImC, including tumor-derived CD11c+ dendritic cells, were able to render T cells nonresponsive. (nih.gov)
  • Thus, this is a first demonstration that in tumor-bearing mice CD8+ T cell tolerance is induced primarily by ImC that may have direct implications for cancer immunotherapy. (nih.gov)
  • B. LN cells isolated from mice after adoptive transfer of OT-1 T cells were incubated in triplicates in the presence of specific (SIINFEKL) (S.P.) or control (RAHYNIVTF) (C.P.) peptides for 24 h. (nih.gov)
  • LN cells isolated from mice as described above were cultured in the presence of specific or control peptide for 24 hr. (nih.gov)
  • LN cells isolated from mice as described above were cultured for 4 days in triplicates in U-bottom 96-well plates (10 5 cells per well) in the presence of 10 μg/ml of specific or control peptide. (nih.gov)
  • E. LN cells isolated from mice after adoptive transfer of 2C T cells were incubated in triplicates in the presence of specific or control peptides for 24 h. (nih.gov)
  • Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice. (nih.gov)
  • regulation
  • In its pattern of expression and/or regulation, MNDA resembles IFI16, suggesting that these genes participate in blood cell-specific responses to interferons. (nih.gov)
  • His research team at University of Notre Dame and Indiana University Simon Cancer Center is actively investigating in-depth mechanisms of myeloid cell regulation and targeting in prostate cancer and other forms of malignancy including rare cancers. (bioconferencelive.com)
  • inhibition
  • In response, tumors reinitiated angiogenesis and immune suppression by activating PI3K signaling in all CD11b+ cells, rendering tumors nonresponsive to VEGF/VEGFR inhibition. (nih.gov)
  • However, PI3K inhibition in CD11b+ myeloid cells generated an enduring angiostatic and immune-stimulatory environment in which antiangiogenic therapy remained efficient. (nih.gov)
  • Systemic pharmacological inhibition of CD95L dampens the peripheral innate response, reduces the accumulation of infiltrating myeloid cells, and efficiently prevents MPTP-induced DN death. (rupress.org)
  • We set out to investigate one possible explanation for the failure of CTLs to eliminate tumors, specifically, the concept that this failure is not dependent on inhibition of T cell function. (nih.gov)
  • acute
  • Over-expression of catalase in myeloid cells confers acute protection following myocardial infarction. (biomedsearch.com)
  • When expressed in the same cells in an inducible manner, catalase showed a time-dependent response with no acute benefit, but a chronic benefit due to altered remodeling. (biomedsearch.com)
  • antibody
  • This Cell Signaling Technology (CST) antibody is conjugated to biotin under optimal conditions. (cellsignal.com)
  • This Cell Signaling Technology antibody is immobilized via covalent binding of primary amino groups to N-hydroxysuccinimide (NHS)-activated Sepharose® beads. (cellsignal.com)
  • Bevacizumab (Avastin), a humanized variant of an anti-VEGF neutralizing monoclonal antibody, is the first antiangiogenic agent to be approved by the Food and Drug Administration for the treatment of metastatic colorectal cancer ( 6 ) and non-small cell lung cancer ( 7 ) in combination with cytotoxic chemotherapy. (aacrjournals.org)
  • Cells were then labeled with anti-CD8-APC and anti-Valpha2- PE antibodies, and then, fixed, permeabilized and stained with anti-IL-2-FITC antibody. (nih.gov)
  • There are currently no images for Myeloid Cell Marker Antibody (NBP2-34759IR). (novusbio.com)
  • vitro
  • Badie B, Schartner J, Klaver J, Vorpahl J (1999) In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. (springer.com)
  • Subsets
  • Our work shows that GMCs are expanded in circulation and TME of CRC patients, which provides further insights for developing immunotherapeutic approaches targeting these cell subsets to enhance antitumor immune and clinical responses. (frontiersin.org)
  • Targets
  • This work provides the first demonstration of siRNA-mediated silencing in myeloid cell types of nonhuman primates (NHPs) and establishes the feasibility of targeting multiple gene targets in rodent myeloid cells. (harvard.edu)
  • G - I ) Experiments were performed essentially as described in A - C , except that EG-7 cells were used as targets instead of peptide-loaded EL-4 cells. (nih.gov)
  • Gene
  • Here, cell lineage tracing revealed that cells in which β-catenin is transcriptionally active express a gene profile that is characteristic of the myeloid lineage. (jci.org)
  • malignant
  • Leukocytes are central regulators of inflammation and the target cells of therapies for key diseases, including autoimmune, cardiovascular, and malignant disorders. (harvard.edu)
  • potent
  • In this report, we develop systemic delivery methods of siRNA encapsulated in lipid nanoparticles (LNP) for durable and potent in vivo RNA interference (RNAi)-mediated silencing in myeloid cells. (harvard.edu)
  • induce
  • ImC are able to take up soluble protein in vivo, process it, and present antigenic epitopes on their surface and induce Ag-specific T cell anergy. (nih.gov)
  • enhances
  • Tasquinimod modulates suppressive myeloid cells and enhances cancer immunotherapies in murine models. (nih.gov)
  • By activating TLR2:TLR6 complexes and inducing TNF-alpha secretion by myeloid cells, versican strongly enhances LLC metastatic growth. (nih.gov)
  • macrophage
  • Our data indicate that β-catenin regulates myeloid cell motility and adhesion and that β-catenin-mediated macrophage motility contributes to the number of mesenchymal cells and ultimate scar size following cutaneous injury. (jci.org)
  • MDSC
  • Tumor cells produce factors that drive the generation of multiple regulatory cells, including CD4 + Th2, T regs , B cells, and MDSC. (nih.gov)
  • Our data therefore suggest what we believe to be a novel mechanism of MDSC-mediated tumor cell resistance to CTLs. (nih.gov)
  • endothelial
  • Joussen AM, Murata T, Tsujikawa A, Kirchhof B, Bursell S-E, Adamis AP (2001) Leukocyte-mediated endothelial cell injury and death in the diabetic retina. (springermedizin.de)
  • distinct
  • Myeloid cells are the most abundant nucleated haematopoietic cells in the human body and are a collection of distinct cell populations with many diverse functions. (nih.gov)
  • These findings identify distinct mechanisms for heat and mechanical hypersensitivity and highlight a crucial contribution of CNS myeloid cells in the facilitation of noxious heat. (ovid.com)
  • contribution
  • however, the relative contribution of β-catenin activity and function in specific cell types in the granulation tissue during the healing process is unknown. (jci.org)
  • Strategies such as bone marrow transplantation may be necessary when SM22α-Cre is used to differentiate the contribution of smooth muscle cells versus myeloid cells to observed phenotypes. (nih.gov)
  • populations
  • p=0.007 for Gr1 + Ly6C Hi cells and TAM versus cognate populations in sorafenib relapse tumors. (nih.gov)
  • 0.05 for TAM, Gr1 + Ly6C Hi and Gr1 + Ly6G Hi cells versus cognate populations in both sorafenib response and relapse phase tumors. (nih.gov)